* If you want to update the article please login/register
OBJECTIVES: Aromatase inhibitors are the first-choice drugs for the treatment of hormone-sensitive breast cancer. METHODS: In 42 randomly chosen rats, persistent estrus was introduced in 42 randomly selected rats to investigate vaginal epithelial cell proliferation by Ki-67 antigen expression. RESULTS: In the case of the experimental group, light microscopy revealed a higher number of cells with brown Ki-67 stained nuclei in the control than in the experimental group. CONCLUSION: This research found that anastrozole, at the dose and treatment duration chosen, significantly reduced cell proliferation in the rats' vaginal mucosa in persistent estrus.
Source link: https://doi.org/10.6061/clinics/2020/e1643
In a HER-2 positive breast cancer patient, the aim of the investigation was to highlight a case of severe meibomian gland dysfunction and conjunctival changes associated with trastuzumab, perceptuzumab, and anastrozole therapy. For several months, a 57-year-old white woman was treated with trastuzumab and pertuzumab biological and anastrozole endocrine therapy for metastatic breast cancer. The patient underwent MGD treatment, but no new conjunctival lesions emerged, subjective signs decreased, and ocular surface morphology remained unchanged during the 18-month follow-up. The disruption of the ocular surface environment was attributed to the novel HER2-inhibitor trastuzumab and pertuzumab biological therapy and anastrozole endocrine therapy. MGD-associated with anticancer therapy can be characterized by the underlying molecular mechanisms. The new histological facet of tarsal conjunctiva changes may help to identify the potential underlying molecular mechanisms. Since anticancer drugs can significantly alter the ocular surface environment, better care of oncology patients can be achieved.
Source link: https://doi.org/10.1159/000524176
We discuss the occurrence of lichen sclerosis of oral cavity in an elderly woman suffering from breast cancer who had the condition while on anastrozole therapy in this interview.
Source link: https://doi.org/10.4103/amhs.amhs_17_17
Methods The PubMed, ClinicalTrials. gov, and Cochrane databases were all systematically reviewed for randomized-controlled trials comparing anastrozole with tamoxifen in early breast cancer treatment. For the remainder of the trials, combined hazard rate was 0. 73 percent, which included hazard rate for recurrence-free survival of estrogen receptor-positive patients for ATAC trials and hazard rate for EFS of all patients. Aromatase inhibitors should be the first hormonal therapy in postmenopausal early breast cancer patients and switching should only be considered for patients who are already receiving tamoxifen.
Source link: https://doi.org/10.1186/1745-6215-9-47
Palbociclib, ribociclib, and abemaciclib were recently approved as chemotherapeutic agents and are now in the post-marketing surveillance phase. They're used in combination with aromatase inhibitors anastrozole and letrozole or antiestrogen fulvestrant for HR+, HER2 U2212 breast cancer treatment. Here, a novel bioanalytical LC-MS/MS scheme was developed for the quantitation of these six drugs in human plasma. In a linear transition, the mobile phase consisted of 0. 1% formic acid in water and ACN in a linear gradient. The intra-day method precision ranged from 3. 7 percent to 15%, although intra-day accuracy was between u22121. 5% and 15. 0%.
Source link: https://doi.org/10.3390/ph15050614
Six months after the birth of anastrozole, she created an irregularly shaped purpuric plaque surrounded the postoperative scar on her left breast. Hormon receptor expression limited to the proliferating and expanding vessels revealed by immunohistochemistry of the skin biopsy specimen revealed hormone receptor expression limited to the vascular endothelial cells. We suspect that anastrozole caused a rise in the local estrogen level, affecting the hormone receptor-positive endothelial cells in the dermis near the primary lesion of breast cancer, and caused a cutaneous adverse event in the aforementioned region.
Source link: https://doi.org/10.1159/000497469
Low testosterone levels in infertile men was as high as 41%, but inadequate seminal characteristics did not necessarily correlate with impaired seminal measurements, according to a study. At 6 and 12 weeks, it was found that there was a significant rise in T level in the CC group vs. the AZ group, however estradiol levels increased in the CC group relative to the AZ group, although estradiol levels increased in the CC group relative to the AZ group.
Source link: https://doi.org/10.4274/jus.2016.03.020
Abstract Background Two cases of acute hepatitis related to anastrozole therapy have been documented before, but the underlying causes of liver injury are currently unclear. Case description A 70-year-old woman developed acute hepatitis during anastrozole therapy with serum antinuclear antibodies; following drug withdrawal, liver function tests were immediately enhanced, and serum auto-antibodies were no longer detectable;.
Source link: https://doi.org/10.1186/1471-230X-11-32
Background BMI has been shown to have a negative effect on estrogenic function in patients receiving anastrozole, resulting in a decreased treatment effect in obese women. Since estradiol is inversely linked to gonadotropins, it can be assumed that an effect of BMI is also shown by gonadotropin plasma concentrations. In addition to estradiol, we'll investigate the effect of BMI on breast cancer patients receiving anastrozole indicated by LH, FSH, and SHBG, as well as estradiol. Methods We determined gonadotropin-, estradiol-, and anastrozole serum samples from postmenopausal, early stage breast cancer patients who received upfront anastrozole after care, which was consistent. In routine quantification, despite aromatase inhibition, 12% of patients had detectable estrogen levels. Obese women have a different hormonal condition than those who take the same dose of anastrozole.
Source link: https://doi.org/10.1186/s12885-017-3208-6
No one knows about the unique medication-taking experiences related to self-management of anastrozole therapy for women with early stage breast cancer. We found that women's side effects experiences, especially menopausal signs, were significant, but only one woman stopped anastrozole due to side effects. Some women related to a shared pill-taking experience with their spouse, but most believed taking anastrozole was something they had to do alone. The findings reveal how some women with early stage breast cancer monitor their hormonal therapy at around the midpoint of diagnosis.
Source link: https://doi.org/10.1155/2012/462121
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions